A Single-Arm Phase II Clinical Trial of Cabozantinib (XL184) in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases With and Without C Met Amplification
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Oct 2019 Status changed from recruiting to completed.
- 20 Aug 2019 Planned primary completion date changed from 1 Jul 2019 to 30 Sep 2019.
- 30 Jul 2018 Planned End Date changed from 1 Jun 2028 to 1 Jul 2024.